LUMBY, B.C., July 10 /PRNewswire-FirstCall/ -- avVaa World Health Care Products, Inc. (OTC Bulletin Board: AVVW), a biotech company offering therapeutic skin and health care products to customers worldwide, is pleased to announce positive findings from a number of scientific studies leading the way to avVaa's next generation of NeuroSkin(TM) products. avVaa Vice President of Research and Development, Dr. Mark Alden, recently presented data from the first clinical trail demonstrating the efficacy of patented nanoparticle silicic acid, the backbone of avVaa's next generation of NeuroSkin products at the plenary session of the New Jersey Technology Council Conference at Princeton University. At the presentation, Dr. Alden explained the vital role that silicon plays (in its biologically active amorphous form) in skin health and resilience (collagen formation, moisture retention, wound healing, among others). The conference, aimed at commercializing nanotechnology in the life sciences, hosted speakers from around the world. Interested parties may download a copy of the presentation materials at: http://www.otcfn.com/avvw or http://www.avvaa.com. The study, soon to be published, was conducted in Munich, Germany on patients suffering from eczema -- for many, a lifelong affliction. Testing both the mild and forte formulations, the study results were very positive. After just four weeks' use of NeuroSkin, researchers noted a 59% decrease in symptoms of erythema, a 70% reduction in skin scaling, a 63% improvement in infiltration, and a 45% reduction in itching. No adverse reactions were reported, and the products were well tolerated by the patients studied: 100% considered the mild version pleasing, and 94% the forte version (scent and irritation). Dr. Alden considered these results "remarkable," and "ground breaking," for a product with no toxicity. Two other studies using nanoparticle silicon were presented at the 42nd National Dermatology Congress, in Rimini, Italy. One, conducted by C. Rigoni, et. al. on children with eczema, and the other by S. Chimenti, et. al. on adults with Psoriasis, showed strikingly similar results. The percentage of patients experiencing greater than 50% reduction in symptoms was 85% and 71% in the two studies, respectively. Ninety percent reported an improvement in the quality of life index. Unlike virtually all commonly prescribed treatments for eczema (including steroids, UV light, coal tar, or chemotherapy), avVaa' NeuroSkin formulation does not require treatment breaks or limited use, since there are no known ill effects or toxicities. NeuroSkin contains silicic acid, a silicon-containing molecule found to be safe for topical application, backed by years of research. Alden continued, "The incidence of common skin ailments is growing worldwide. Yet, for the millions of people suffering from eczema and psoriasis, no cure is in sight. The only current palliative treatments available come with a risk of adverse effects, and their use must be limited. avVaa World Health Care Products, using a patented process that refines silica to nanoparticle size, provides a non-toxic solution for patients suffering from this growing health problem. "The results of these studies conducted around the world, together with ongoing trials, support our current line, and lead the way to new products under development -- including new applications and next generation formulations of NeuroSkin, which we are very excited about." avVaa CEO and Director Jack Farley said, "We are encouraged by recent study findings on our newest product lines. Well-researched, controlled scientific studies as to efficacy and safety lend substantial credibility in the marketplace and we look forward to full introduction of these unique skin care products that will meet avVaa's strictest standards for non-toxic, therapeutic skin care products to improve quality of life and well being for consumers worldwide." About avVaa World Health Care Products avVaa World Health Care Products is a global biotechnology company that specializes in effective, non-toxic, therapeutic skin care products that improve quality of life and well being for consumers. The Company's patented European skin care formulas are scientifically registered, FDA-Compliant, and were developed to relieve and treat the symptoms of common skin ailments, including: eczema, psoriasis and acne. Many avVaa products are already available for over-the-counter purchase at: http://www.help4skincare.com. avVaa is poised to manufacture and market its OTC NeuroSkin(TM) line of skin care products through mass, food and drug channels in the United States and globally. The Company's secondary line of equine and pet care related products are already being distributed throughout all of Canada and parts of the United States. For more information, visit: http://www.avvaa.com or http://www.otcfn.com/avvw. Contact: Merle Goertz (West Coast) of avVaa World Health Care Products, 1- 604-688-2349 or Rick McCaffrey at OTC Financial Network, Investor Relations, 781-444-6100 x625. Safe Harbor: Statements contained in this press release that are not based upon current or historical fact are forward looking in nature. Such forward- looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of avVaa World Health Care Products, Inc. and no assurance can be given that such results will be achieved. Potential risks and uncertainties include but are not limited to the ability to procure, properly price, retain, and successfully complete projects, the availability of technical personnel, changes in technology, and competition.
SOURCE avVaa World Health Care Products, Inc.